Unique infectious profile of novel coronavirus makes COVID-19 difficult to treat: Lancet | The Weather Channel – Articles de The Weather Channel

As COVID-19 cases increase around the world, leaving many of us wondering why it’s so difficult to treat, a review published in the prestigious journal The Lancet revealed that the increase in the number of cases is due to a unique infectious profile.

According to the review, there is growing evidence that the virus infects both the upper and lower respiratory tract.

The review suggests that it is different from the “low pathogenic” human coronavirus subspecies, which typically settle in the upper respiratory tract and cause cold-like symptoms or “highly pathogenic” viruses such as those that cause SARS and ARDS, which usually settle in the lower respiratory tract.

Additionally, more frequent multi-organ impacts, blood clots, and an unusual immune-inflammatory response that is not usually associated with other similar viruses, mean that COVID-19 has developed a particularly difficult set of characteristics.

“The emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which causes COVID-19, has resulted in a health crisis that has not been witnessed since the Spanish flu pandemic of 1918. Tragically , millions of people around the world have already died, “said co-author Ignacio Martin-Loeches, clinical professor at Trinity College Dublin.

While animal and experimental models imply that an overly aggressive immune-inflammatory response is a key factor, it appears that things work differently in humans – although inflammation is a factor, it is a unique deregulation of the immune response that causes our body to mismanage the way it fights the virus.

“Despite the international attention to the virus, we are only just beginning to understand its intricacies,” said Martin-Loeches.

“Based on growing evidence, we propose that COVID-19 should be viewed as a new entity with a previously unknown infectious profile. It has its own distinct characteristics and pathophysiology and we need to be aware of this when treating people.” , added Martin-Loeches. .

However, the co-author also said that doesn’t mean we should abandon existing best practice treatments based on our knowledge of other human coronaviruses.

But an impartial and progressive assembly of the main pieces of the COVID-19 puzzle for different cohorts of patients – based on gender, age, ethnicity, pre-existing co-morbidities – is what is needed to modify them. existing treatment guidelines, and then provide the most appropriate care. COVID-19 patients.

**

The above article was published by a news agency with minimal changes to the title and text.


Source link

About Cecil Cobb

Check Also

Braxia Scientific Introduces ‘Braxia Health’, a Growing Network of Clinics Leading Research and Innovative Psychedelic Treatments for Mental Disorders

Braxia Scientific enters new chapter as it begins operations under its new symbol “CSE: BRAX” …

Leave a Reply

Your email address will not be published. Required fields are marked *